New hope for rare obesity syndromes? weekly injection trial begins
NCT ID NCT06901245
Summary
This study is testing how well a weekly weight loss medication called tirzepatide works for one year in young adults (ages 18-26). It aims to compare its effects in people with rare, hard-to-treat obesity from genetic conditions like Prader-Willi Syndrome against those with general obesity. Researchers will track changes in weight, body fat, appetite, and blood markers to see if the drug helps control weight and related health issues.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRADER-WILLI SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Children's Minnesota
RECRUITINGSaint Paul, Minnesota, 55102, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Seattle Children's Hospital
RECRUITINGSeattle, Washington, 98105, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
-
Vanderbilt University Medical Center
RECRUITINGNashville, Tennessee, 37203, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.